Biomaterial Database

Double-blind placebo--controlled trial of nandrolone decanoate in postmenopausal osteoporosis. 1998

M Chhaparwal, and M L Saraf

Dept KEM Hospital, Bombay.

UI	MeSH Term	Description	Entries
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009277	Nandrolone	C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.	19-Nortestosterone,Estrenolone,Norandrostenolone,Nortestosterone,17-Hydroxy-Estr-4-Ene-3-One,17beta-Hydroxy-19-Nor-4-Androsten-3-One,17beta Hydroxy 19 Nor 4 Androsten 3 One
D004311	Double-Blind Method	A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.	Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077603	Nandrolone Decanoate	Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.	17 beta-Hydroxyestr-4-en-3-one 17-decanoate,19-Nortestosterone Decanoate,19-nor-4-Androstene-17 beta-ol-3-one 17-decanoate,Decadurabolin,Decadurobolin,Retabolil,Retabolyl,17 beta Hydroxyestr 4 en 3 one 17 decanoate,19 Nortestosterone Decanoate,19 nor 4 Androstene 17 beta ol 3 one 17 decanoate
D015519	Bone Density	The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.	Bone Mineral Content,Bone Mineral Density,Bone Densities,Bone Mineral Contents,Bone Mineral Densities,Density, Bone,Density, Bone Mineral
D015663	Osteoporosis, Postmenopausal	Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.	Bone Loss, Perimenopausal,Bone Loss, Postmenopausal,Perimenopausal Bone Loss,Postmenopausal Bone Loss,Postmenopausal Osteoporosis,Osteoporosis, Post-Menopausal,Bone Losses, Perimenopausal,Bone Losses, Postmenopausal,Osteoporoses, Post-Menopausal,Osteoporoses, Postmenopausal,Osteoporosis, Post Menopausal,Perimenopausal Bone Losses,Post-Menopausal Osteoporoses,Post-Menopausal Osteoporosis,Postmenopausal Bone Losses,Postmenopausal Osteoporoses
D045930	Anabolic Agents	These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power.	Anabolic Effect,Anabolic Effects,Agents, Anabolic,Effect, Anabolic,Effects, Anabolic

Related Publications

M Chhaparwal, and M L Saraf

Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate.

January 1993, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,

M Chhaparwal, and M L Saraf

The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial.

May 2005, The journals of gerontology. Series A, Biological sciences and medical sciences,

M Chhaparwal, and M L Saraf

Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study.

July 1991, Calcified tissue international,

M Chhaparwal, and M L Saraf

[Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].

January 1989, Minerva endocrinologica,

M Chhaparwal, and M L Saraf

Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study.

September 1989, Maturitas,